U.S. markets closed

TG Therapeutics, Inc. (TGTX)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
15.21-0.36 (-2.31%)
Al cierre: 04:00PM EDT
15.37 +0.16 (+1.05%)
Fuera de horario: 07:52PM EDT

TG Therapeutics, Inc.

3020 Carrington Mill Blvd.
Suite 475
Morrisville, NC 27560
United States
212 554 4484
https://www.tgtherapeutics.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo264

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Michael S. Weiss Esq.Chairman, CEO & President1.97MN/D1966
Mr. Sean A. Power CPACFO, Corporate Secretary & Treasurer652.6kN/D1982
Jenna BoscoSenior Vice President of Corporate CommunicationsN/DN/DN/D
Mr. Adam WaldmanChief Commercialization OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Gestión corporativa

La calificación ISS Governance QuickScore de TG Therapeutics, Inc. a partir del 1 de marzo de 2024 es 10. Las puntuaciones principales son Auditoría: 4; Junta: 10; Derechos del accionista: 5; Compensación: 10.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.